Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HELIOS/IKZF2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IKZF2 (HELIOS) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for biochemical binding and E3 ligase recruitment assays. |
View IKZF2 Products |
| Gene Delivery | IKZF2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and intracellular degradation assays. |
View IKZF2 Products |
| Benchmark Ab | Anti-IKZF2 Recombinant Antibody Recombinant positive control for Western Blot, Flow Cytometry, and IHC validation. |
View IKZF2 Products |
| Validator | IKZF2 siRNA Set Target-specific knockdown verification in primary T cells and tumor cell lines. |
View IKZF2 Products |
| Related Target A | IKZF1 (Ikaros) Essential for off-target selectivity profiling of molecular glues and CELMoDs. |
View IKZF1 Products |
| Related Target B | CRBN (Cereblon) Primary E3 ligase partner utilized by molecular glues targeting IKZF2 for degradation. |
View CRBN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against homologous zinc finger proteins (IKZF1/3/4) | Full panel of Ikaros family recombinant proteins available with sequence verification and >95% purity. |
| Ternary complex (CRBN-Glue-IKZF2) characterization | High-purity, low-endotoxin CRBN and IKZF2 proteins optimized for SPR, FP, and TR-FRET assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Degradation Screens | Validated siRNA included for specificity checks and target validation |
Live HELIOS/IKZF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HELIOS/IKZF2 therapeutics is intensifying, with major players shifting focus from traditional target inhibition to Targeted Protein Degradation (TPD). As first-generation molecular glues reach the clinic, the next wave of R&D is targeting selective IKZF2 degradation to reprogram regulatory T cells (Tregs) within the tumor microenvironment without inducing systemic lymphoid toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glues (CELMoDs) | Novartis, Astellas, Bristol Myers Squibb | Solid Tumors, AML, B-cell Malignancies | Ternary Complex Formation Assay (Need high-purity IKZF2 and CRBN proteins) |
| PROTACs | Arvinas, Monte Rosa Therapeutics | Advanced Solid Tumors | Kinetics of Degradation (Need Lentivirus for stable reporter cell line construction) |
| Immunotherapy (Treg depletion) | Academic institutions, Biotech startups | Immuno-oncology combinations | In vitro Treg Phenotyping (Need validated IKZF2 antibodies and siRNA) |